0001213900-24-015887.txt : 20240222 0001213900-24-015887.hdr.sgml : 20240222 20240221195441 ACCESSION NUMBER: 0001213900-24-015887 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20240222 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALTERITY THERAPEUTICS LTD CENTRAL INDEX KEY: 0001131343 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49843 FILM NUMBER: 24661848 BUSINESS ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 BUSINESS PHONE: 61 3 9349 4906 MAIL ADDRESS: STREET 1: LEVEL 3, 460 BOURKE STREET CITY: MELBOURNE STATE: C3 ZIP: VIC 3000 FORMER COMPANY: FORMER CONFORMED NAME: PRANA BIOTECHNOLOGY LTD DATE OF NAME CHANGE: 20010105 6-K 1 ea0200447-6k_alterity.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2024

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒       Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1  

Trading Halt

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alterity Therapeutics Limited
   
  By:  /s/ Geoffrey P. Kempler
    Geoffrey P. Kempler
    Chairman

 

Date: February 22, 2024

 

 

2

 

 EX-99.1 2 ea0200447ex99-1_alterity.htm TRADING HALT

Exhibit 99.1

 

 

 

Market Announcement

 

22 February 2024

 

 

Alterity Therapeutics Limited (ASX: ATH) – Trading Halt

 

Description

 

The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 26 February 2024 or when the announcement is released to the market.

 

Issued by

 

ASX Compliance

 

 

22 February 2024Market Announcement 1/1
ASX LimitedASX Customer Service Centre 131 279 | asx.com.au

 

 

 

 

 

 

22 February 2024

 

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

ASX Compliance Pty Ltd

Level 50, South Tower, Rialto

525 Collins St

Melbourne VIC 3000

 

By email:TradingHaltsMelbourne@asx.com.au
 ListingsComplianceMelbourne@asx.com.au

 

Dear Melissa

 

Request for a trading halt – Alterity Therapeutics Limited

 

In accordance with ASX Listing Rule 17.1, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (the Company) requests that its securities be placed into an immediate trading halt pending an announcement in relation to a capital raise.

 

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Monday, 26 February 2024, whichever is the earlier.

 

The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.

 

Please contact me if you require any further information.

 

Yours sincerely

 

Phillip Hains

Company Secretary

 

 

Alterity Therapeutics Limited ABN 37 080 699 065

Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia

T: +61 (0)3 9349 4906 | www.alteritytherapeutics.com

 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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ⅅ!DZG9B!U)X>(;6WBN/!5I'!$EL+U2(50!!A,C MY>G!HHKKK[Q^?Y&-/J=-XEBCF\+ZI'*BNAM9,JPR#\I[5X7::IJ$5E!''?W2 5(L:JJK,P ' S116.'^%EU=S__9 end GRAPHIC 4 ex99-1_002.jpg GRAPHIC begin 644 ex99-1_002.jpg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end GRAPHIC 5 ex99-1_003.jpg GRAPHIC begin 644 ex99-1_003.jpg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end